Anti-Obesity Drugs Market to Reach $104.9 Billion by 2035, Growing at 18.3% CAGR | Eli Lilly, Novo Nordisk, Boehringer Ingelheim

Roots Analysis has published a new market intelligence report finding that the global anti-obesity drugs market, valued at USD 12.8 billion in 2024, will climb to USD 19.6 billion in 2025 and USD 104.9 billion by 2035, advancing at a compound annual growth rate (CAGR) of 18.3% over the forecast period. The scale of this expansion reflects a healthcare system finally treating obesity as the chronic, systemic disease it is, rather than a lifestyle failure amenable to willpower alone.

To explore the complete findings, request a free sample of the report at https://www.rootsanalysis.com/reports/anti-obesity-drugs-market/request-sample.html

Market Overview: A Global Health Crisis Creates a Multi-Billion-Dollar Imperative
The numbers driving this market are not speculative. The World Health Organization reports that global obesity rates have nearly tripled since 1975, with more than 2 billion adults now classified as overweight and at least 650 million considered clinically obese. In the United States alone, approximately 40% of adults carry a BMI of 30 or higher. Obesity is not an isolated condition; it is a gateway to type 2 diabetes, cardiovascular disease, and certain cancers, generating cascading healthcare costs that governments and insurers can no longer absorb through inaction.

Anti-obesity medications address this crisis by targeting the biological mechanisms that regulate appetite, fat absorption, and metabolism. The newest generation of drugs, specifically GLP-1 receptor agonists and their multi-action successors, has moved the field far beyond the blunt interventions of the past. In November 2023, the U.S. FDA approved Eli Lilly's Zepbound (tirzepatide) for chronic weight management in adults, a milestone that validated the dual GLP-1/GIP agonist class and set off a wave of competitive investment across the sector.

Public and private capital is converging on this space at a rate not seen in prior decades. Roche acquired Carmot Therapeutics for USD 2.7 billion plus USD 400 million in milestones in January 2024, securing access to clinical-stage obesity assets including lead compound CT-388. That same month, Eli Lilly launched LillyDirect, a telehealth-integrated platform designed to improve patient access to Zepbound. Mankind Pharma disclosed in February 2025 that it is developing an oral small-molecule anti-obesity candidate, currently progressing to Phase II trials in Australia. Eli Lilly also launched Mounjaro (tirzepatide) in the Indian market in March 2025, pricing it at INR 3,500 for a 2.5 mg vial, signaling the beginning of geographic expansion into high-population emerging markets.

Key Growth Drivers
Surging global obesity prevalence. With over 650 million adults classified as obese worldwide, the patient population requiring pharmacological intervention is substantial and still growing. Sedentary lifestyles, ultra-processed food environments, and genetic predisposition are sustaining this trend across both developed and developing economies. Governments and health systems are responding with formal obesity management programs that increasingly include pharmacotherapy as a first-line option.

Regulatory momentum and landmark drug approvals. Regulatory agencies in the U.S. and Europe have moved from skepticism to active support for anti-obesity drug development. The FDA's approval of Wegovy (semaglutide) and Zepbound (tirzepatide) created a clinical and commercial template that competitors are now building on. Close to 120 anti-obesity programs are currently in clinical trials, reflecting the industry's confidence that the regulatory environment will continue to reward well-designed therapies.

Innovation in drug mechanisms and compound classes. The shift from single-agonist to dual-agonist and tri-agonist compounds represents a genuine scientific advance, not incremental iteration. Tirzepatide's dual action on GLP-1 and GIP receptors produces superior weight loss outcomes compared to GLP-1 agonists alone, and tri-agonists targeting GLP-1, GIP, and glucagon receptors simultaneously are now entering clinical evaluation. Novel compounds including leptin analogs and MC4R agonists add further depth to the pipeline.

Telehealth and digital health integration. Anti-obesity drugs work best when combined with structured lifestyle interventions, and the expansion of telemedicine platforms has made that combination far more accessible. Eli Lilly's LillyDirect is an early example of pharma companies building direct-to-patient digital channels. Broader telehealth adoption is increasing adherence to treatment regimens and expanding the reachable patient population well beyond traditional clinic settings.

Personalized medicine and pharmacogenomics. As healthcare moves toward individualized treatment, anti-obesity pharmacotherapy is following. Research into patient-specific metabolic profiles and genetic responses to GLP-1 therapy is producing evidence that tailored treatment selection can significantly improve outcomes, supporting premium pricing and sustained utilization.

Market Segmentation: Where the Opportunity Concentrates
The anti-obesity drugs market segments across type of molecule, active compound, mechanism of action, agonist type, action pathway, route of administration, and geography.

Small molecules currently lead by type of molecule, capturing 54% of the overall market, owing to their established safety profiles, lower production costs, and ease of administration. However, biologics are gaining ground as more effective alternatives targeting the underlying biological pathways of obesity and are expected to take a larger share through 2035. By active compound, semaglutide holds the largest current share due to its strong efficacy as a GLP-1 receptor agonist, but tirzepatide is forecast to surpass it as clinical evidence supporting its dual-mechanism superiority accumulates. In terms of agonist type, single-agonists account for 68% of the market today, though dual-agonists are attracting accelerating investment as personalized treatment protocols become standard practice.

By action pathway, centrally acting agents dominate with an 86% share, reflecting their proven ability to modulate hunger signals through direct interaction with the central nervous system. By route of administration, parenteral formulations command 98% of the market, driven by their higher bioavailability and more predictable dosing profiles compared to oral options, though oral candidates such as orforglipron and oral semaglutide represent the next frontier of patient convenience.

To request quote of this report, please visit: https://www.rootsanalysis.com/reports/anti-obesity-drugs-market/request-quote.html

Regional Insights: North America Leads, Asia-Pacific Accelerates
North America holds approximately 70% of the global anti-obesity drugs market and is expected to maintain that dominant position through 2035. The region benefits from a high obesity prevalence, advanced healthcare infrastructure, significant pharmaceutical R&D investment, and regulatory frameworks that set global standards. Roughly 55% of all anti-obesity drug developers worldwide are headquartered in North America, cementing its role as the primary engine of both innovation and commercial deployment.

Europe ranks second, supported by established national health systems that are increasingly covering anti-obesity therapies as the medical evidence base strengthens. Asia-Pacific, however, is the region to watch: it is forecast to grow at a CAGR of approximately 40% through 2035, the highest of any geography covered in the report. China is the dominant hub for drug developers within the region, followed by South Korea. Eli Lilly's March 2025 India launch of Mounjaro illustrates the commercial logic of targeting Asia-Pacific's vast underserved patient population, and more multinational market entries are expected to follow.

Competitive Landscape: 123 Players, Intensifying Consolidation
The anti-obesity drugs market features 123 active drug developers, including Eli Lilly, Pfizer, Regeneron, Kallyope, CinFina Pharma, Viking Therapeutics, AstraZeneca, Novo Nordisk, Roche, Adocia, Boehringer Ingelheim, Zealand Pharma, Hanmi Pharm, Jiangsu Hengrui Pharmaceuticals, Gmax Biopharma, PegBio, QL Biopharm, and Sciwind Biosciences. Notably, 35% of these companies were established after 2015, signaling that the opportunity is attracting a sustained wave of new entrants rather than consolidating prematurely around incumbents.

The primary competitive battleground is clinical differentiation: companies are racing to demonstrate that their multi-agonist compounds can deliver greater weight loss with better tolerability than first-generation GLP-1 therapies. M&A is an active secondary strategy, as large-cap pharma firms acquire early-stage assets to fill pipeline gaps quickly, as illustrated by Roche's Carmot acquisition. Pricing, market access, and injectable-to-oral formulation transitions are expected to define competitive positioning through the latter half of the forecast period.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/anti-obesity-drugs-market.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.